Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784300 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of PTI-125 in Healthy Volunteers
A Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset, sponsored by Pain Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03784300: Completed Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset, sponsored by Pain Therapeutics.
NCT03784300 is a Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset that has completed, run by Pain Therapeutics. The registered enrollment target is 24 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03784300, a Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset, has completed, sponsored by Pain Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
Primary Outcome
The peak drug concentration will be obtained directly from the data without interpolation.
Conditions Studied
Interventions
- DRUG 50 mg PTI-125
- DRUG 100 mg PTI-125
- DRUG 200 mg PTI-125
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2018-03-27 |
| Phase | Phase 1 |
What the finished NCT03784300 record still lists
NCT03784300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which 50 mg PTI-125 is the first listed.
NCT03784300 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03784300 about?
NCT03784300 is a clinical study titled "A Safety Study of PTI-125 in Healthy Volunteers". A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
What is the current status of trial NCT03784300?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-08-18. Estimated completion is 2018-03-27.
What conditions does trial NCT03784300 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Disease, Early Onset.
What interventions are being tested in trial NCT03784300?
The interventions under investigation include: 50 mg PTI-125 (DRUG), 100 mg PTI-125 (DRUG), 200 mg PTI-125 (DRUG).
Who is sponsoring clinical trial NCT03784300?
This trial is sponsored by Pain Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784300 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03784300's enrollment target sits among peer trials
24 258th of 306 higher than 45 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI